These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10123669)

  • 21. Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?
    Fant WK
    Pharmacoeconomics; 1993 Jun; 3(6):437-45. PubMed ID: 10146878
    [No Abstract]   [Full Text] [Related]  

  • 22. How Genentech Novartis stifled a promising drug: biotech firm tried to pursue a peanut allergy inject, but contract got in way; Zach avoids a "kiss of death".
    Hamilton DP
    Wall St J (East Ed); 2005 Apr; ():A1, A10. PubMed ID: 15926244
    [No Abstract]   [Full Text] [Related]  

  • 23. Just mad about mAbs.
    Jacobs T
    Nat Biotechnol; 2002 Sep; 20(9):869. PubMed ID: 12205498
    [No Abstract]   [Full Text] [Related]  

  • 24. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
    Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
    Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
    [No Abstract]   [Full Text] [Related]  

  • 25. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 26. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 27. Multidrug-resistant Gram-negative bacterial infections: the emerging threat and potential novel treatment options.
    Vergidis PI; Falagas ME
    Curr Opin Investig Drugs; 2008 Feb; 9(2):176-83. PubMed ID: 18246520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tysabri's troubles return.
    Hoag H
    Nat Biotechnol; 2008 Oct; 26(10):1061. PubMed ID: 18846062
    [No Abstract]   [Full Text] [Related]  

  • 29. Teicoplanin in the therapy of gram-positive infections: an open non-randomized study.
    De Lalla F; Rinaldi E; Santoro D; Rizzardini G; Martello P; Guaglianone MH
    J Chemother; 1989 Jul; 1(4 Suppl):719-21. PubMed ID: 16312606
    [No Abstract]   [Full Text] [Related]  

  • 30. Search for sepsis drugs goes on despite past failures.
    Stone R
    Science; 1994 Apr; 264(5157):365-7. PubMed ID: 8153620
    [No Abstract]   [Full Text] [Related]  

  • 31. Ambulatory treatment with intramuscular ceftriaxone.
    Schlaeffer F
    J Chemother; 1989 Jul; 1(4 Suppl):655-6. PubMed ID: 16312577
    [No Abstract]   [Full Text] [Related]  

  • 32. Next-generation monoclonals less profitable than trailblazers?
    Mitchell P
    Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
    [No Abstract]   [Full Text] [Related]  

  • 33. Ethics, money & negative studies.
    Friedman JH
    Med Health R I; 2001 Mar; 84(3):74. PubMed ID: 11280131
    [No Abstract]   [Full Text] [Related]  

  • 34. Tigecycline: clinical evidence and formulary positioning.
    Nathwani D
    Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is in the pipeline for Gram-negative pathogens?
    Talbot GH
    Expert Rev Anti Infect Ther; 2008 Feb; 6(1):39-49. PubMed ID: 18251663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antiendotoxin agent HA-1A (Centoxin).
    Inglis TJ; Hawkey PM; Lacey RW; Bodeham A; Kay E; Calvert RT
    Lancet; 1993 Jan; 341(8840):303. PubMed ID: 8093933
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug discovery. Magnificent obsession.
    Couzin J
    Science; 2005 Mar; 307(5716):1712-5. PubMed ID: 15774740
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical research: outlook from industry.
    Echols R
    Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
    [No Abstract]   [Full Text] [Related]  

  • 39. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 40. Tysabri back on market.
    Sheridan C
    Nat Biotechnol; 2006 Aug; 24(8):874. PubMed ID: 16900111
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.